A safety and pharmacokinetic study of intravenous natalizumab in patients with MS

William Sheremata, T. L. Vollmer, L. A. Stone, A. J. Willmer-Hulme, M. Koller

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

A phase 1, randomized, placebo-controlled, five-level dose escalation safety and tolerability and pharmacokinetic study of a single IV dose of natalizumab was performed. Doses of 0.03 to 3.0 mg/kg natalizumab or placebo were studied in 28 stable relapsing-remitting or secondary-progressive MS. All doses were safe and well tolerated in MS. Serum concentrations of natalizumab are detectable for 3 to 8 weeks after a single 1- or 3-mg/kg IV dose and justify controlled efficacy studies.

Original languageEnglish
Pages (from-to)1072-1074
Number of pages3
JournalNeurology
Volume52
Issue number5
StatePublished - Mar 23 1999

Fingerprint

Pharmacokinetics
Safety
Placebos
Serum
Natalizumab

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Sheremata, W., Vollmer, T. L., Stone, L. A., Willmer-Hulme, A. J., & Koller, M. (1999). A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology, 52(5), 1072-1074.

A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. / Sheremata, William; Vollmer, T. L.; Stone, L. A.; Willmer-Hulme, A. J.; Koller, M.

In: Neurology, Vol. 52, No. 5, 23.03.1999, p. 1072-1074.

Research output: Contribution to journalArticle

Sheremata, W, Vollmer, TL, Stone, LA, Willmer-Hulme, AJ & Koller, M 1999, 'A safety and pharmacokinetic study of intravenous natalizumab in patients with MS', Neurology, vol. 52, no. 5, pp. 1072-1074.
Sheremata W, Vollmer TL, Stone LA, Willmer-Hulme AJ, Koller M. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology. 1999 Mar 23;52(5):1072-1074.
Sheremata, William ; Vollmer, T. L. ; Stone, L. A. ; Willmer-Hulme, A. J. ; Koller, M. / A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. In: Neurology. 1999 ; Vol. 52, No. 5. pp. 1072-1074.
@article{66993ee9c2c549fda470f937849b6daf,
title = "A safety and pharmacokinetic study of intravenous natalizumab in patients with MS",
abstract = "A phase 1, randomized, placebo-controlled, five-level dose escalation safety and tolerability and pharmacokinetic study of a single IV dose of natalizumab was performed. Doses of 0.03 to 3.0 mg/kg natalizumab or placebo were studied in 28 stable relapsing-remitting or secondary-progressive MS. All doses were safe and well tolerated in MS. Serum concentrations of natalizumab are detectable for 3 to 8 weeks after a single 1- or 3-mg/kg IV dose and justify controlled efficacy studies.",
author = "William Sheremata and Vollmer, {T. L.} and Stone, {L. A.} and Willmer-Hulme, {A. J.} and M. Koller",
year = "1999",
month = "3",
day = "23",
language = "English",
volume = "52",
pages = "1072--1074",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - A safety and pharmacokinetic study of intravenous natalizumab in patients with MS

AU - Sheremata, William

AU - Vollmer, T. L.

AU - Stone, L. A.

AU - Willmer-Hulme, A. J.

AU - Koller, M.

PY - 1999/3/23

Y1 - 1999/3/23

N2 - A phase 1, randomized, placebo-controlled, five-level dose escalation safety and tolerability and pharmacokinetic study of a single IV dose of natalizumab was performed. Doses of 0.03 to 3.0 mg/kg natalizumab or placebo were studied in 28 stable relapsing-remitting or secondary-progressive MS. All doses were safe and well tolerated in MS. Serum concentrations of natalizumab are detectable for 3 to 8 weeks after a single 1- or 3-mg/kg IV dose and justify controlled efficacy studies.

AB - A phase 1, randomized, placebo-controlled, five-level dose escalation safety and tolerability and pharmacokinetic study of a single IV dose of natalizumab was performed. Doses of 0.03 to 3.0 mg/kg natalizumab or placebo were studied in 28 stable relapsing-remitting or secondary-progressive MS. All doses were safe and well tolerated in MS. Serum concentrations of natalizumab are detectable for 3 to 8 weeks after a single 1- or 3-mg/kg IV dose and justify controlled efficacy studies.

UR - http://www.scopus.com/inward/record.url?scp=0033596831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033596831&partnerID=8YFLogxK

M3 - Article

C2 - 10102433

AN - SCOPUS:0033596831

VL - 52

SP - 1072

EP - 1074

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 5

ER -